ANNX — Annexin Pharmaceuticals AB (publ) Share News
0.000.00%
Last trade - 00:00- SEK55.46m
- SEK50.19m
Brief: Annexin Pharmaceuticals Proposes A Fully Guaranteed Rights Issue Of Units Of SEK 73.5 Million
Brief: Annexin Publishes Positive Results In Co's Phase 1-Study
Brief: Annexin Q2 Net Loss Narrows To SEK 9.0 Mln
Brief: Annexin Pharmaceuticals In Collaboration For Covid-19 Study
Brief: Annexin Pharmaceuticals Starts Cooperation With Tracer
Brief: Annexin Pharmaceuticals Q3 Net Loss Widens To SEK 8.2 Million
Brief: Annexin Pharmaceuticals: Publication Points To Possibility Of Treating COVID-19 With ANXV
Brief: Annexin Q2 Net Loss Widens To SEK 11.6 Million
Brief: Annexin Says Annexin A5 May Be Relevant As Treatment For Covid-19
Brief: Annexin Pharmaceuticals Q1 Net Loss Widens To SEK 8.1 Mln
Brief: Annexin Pharmaceuticals Gets Patent Approval In Japan
Brief: Annexin To Temporarily Withdraw Application For Clinical Study
Brief: Annexin Pharmaceuticals Rights Issue Oversubscribed
Brief: Annexin Pharmaceuticals Q4 Results At -10 356 TSEK
Brief: Annexin Pharmaceuticals Carries Out Rights Issue Of Around SEK 61 Mln
Brief: Annexin Pharmaceuticals Q3 Net Loss Widens To SEK 6.5 Mln
Brief: Annexin Pharmaceuticals Appoints Anders Haegerstrand CEO
Brief: Annexin Pharmaceuticals Q2 Net Loss Narrows To SEK 6.0 Mln
Brief: Annexin Pharmaceuticals CEO Jamal El-Mosleh Resigns